Anselm Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 14 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.50 Cr
- Revenue Growth -56.73%
- Profit Growth -94.39%
- Ebitda -481.74%
- Net Worth 4.70%
- Total Assets 17.96%
About Anselm Pharmaceuticals
Anselm Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 February 2016 (Nine years 14 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.50 Cr.
Rajshri Dhamankar and Siddhi Parab serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74994MH2016PTC272897
- Company No.
272897
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Feb 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Anselm Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajshri Dhamankar  | Additional Director | 21-Dec-2022 | Current |
| Siddhi Parab | Additional Director | 21-Dec-2022 | Current |
Financial Performance of Anselm Pharmaceuticals.
Anselm Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 56.73% decrease. The company also saw a substantial fall in profitability, with a 94.39% decrease in profit. The company's net worth moved up by a moderate rise of 4.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anselm Pharmaceuticals?
In 2021, Anselm Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹15.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 1.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Mar 2021 | Hdfc Bank Limited | ₹1.50 Cr | Open |
How Many Employees Work at Anselm Pharmaceuticals?
Unlock and access historical data on people associated with Anselm Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anselm Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anselm Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
